Claire Arbaud

RBM10‐TFE3 fusions: A FISH‐concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases

N. Rioux-Leclercq, M. Sibony, V. Molinie, 2021, Genes, chromosomes & cancer.

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.

F. Bonnetain, P. Hammel, A. Gramont, 2015 .

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Christophe Tournigand, Franck Bonnetain, Olivier Dupuis, 2016, Cancer medicine.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

P. Rougier, F. Bonnetain, P. Hammel, 2015 .

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.